Urology,also known as genitourinary surgery,is the branch of medicine that focuses on surgical and medical diseases of the urinary-tract system and the reproductive organs. Organs under the domain of urology include the kidneys,adrenal glands,ureters,urinary bladder,urethra,and the male reproductive organs.
Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.
James Larue Mohler is a urologist at Roswell Park. Mohler joined Roswell Park in 2003 as Chair of Urology and Leader of the Prostate Program. He became the associate director and Senior Vice President for Translational Research. He is Chair Emeritus,Urology,and Chief,Inter-Institutional Academics,and Professor of Oncology at Roswell Park Comprehensive Cancer Center,and adjunct professor of Urology and Member of UNC-Lineberger Comprehensive Cancer Center at University of North Carolina.
Abigail Alliance for Better Access to Developmental Drugs v. von Eschenbach,495 F.3d 695,cert denied,552 U.S. 1159 (2008) was resolved in early 2008 when the Supreme Court of the United States declined to hear the appeal. Their refusal left standing the appellate court decision,which said that patients have no right to "a potentially toxic drug with no proven therapeutic benefit."
Ashutosh K. Tewari is the chairman of urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City. He is a board certified American urologist,oncologist,and principal investigator. Before moving to the Icahn School of Medicine in 2013,he was the founding director of both the Center for Prostate Cancer at Weill Cornell Medical College and the LeFrak Center for Robotic Surgery at NewYork–Presbyterian Hospital. Dr. Tewari was the Ronald P. Lynch endowed Chair of Urologic Oncology and the hospital's Director of Robotic Prostatectomy,treating patients with prostate,urinary bladder and other urological cancers. He is the current President of the Society for Urologic Robotic Surgeons (SURS) and the Committee Chair of the Prostate Program. Dr. Tewari is a world leading urological surgeon,and has performed over 10,000 robotically assisted procedures using the da Vinci Surgical System. Academically,he is recognized as a world-renowned expert on urologic oncology with over 250 peer reviewed published papers to his credit;he is on such lists as America's Top Doctors,New York Magazine's Best Doctors,and Who's Who in the World. In 2012,he was given the American Urological Association Gold Cystoscope Award for "outstanding contributions to the field of urologic oncology,most notably the treatment of prostate cancer and the development of novel techniques to improve the outcomes of robotic prostatectomy."
Douglas S. Scherr,M.D. is an American surgeon and specialist in Urologic Oncology. He is currently the Clinical Director of Urologic Oncology at Weill Cornell Medicine. He also holds an appointment at the Rockefeller University as a Visiting Associate Physician. Scherr was the first physician at Cornell to perform a robotic prostatectomy as well as a robotic cystectomy.
Johannes W. Vieweg is an American medical school dean,university professor,and physician-scientist,presently residing in the city of Fort Lauderdale,Florida.
John E. Niederhuber,MD was the 13th director of the National Cancer Institute (NCI),from 2006 until July,2010,succeeding Andrew von Eschenbach,who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher,Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor,cancer center director,National Cancer Advisory Board chair,external advisor to the NCI,grant reviewer,and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director,Johns Hopkins Clinical Research Network.
Simon J. Hall is an American researcher who is the Associate Professor and Kyung Hyun Kim,M.D. Chair of Urology and Assistant Professor,Department of Gene and Cell Medicine at The Mount Sinai School of Medicine,as well as the Director of the Barbara and Maurice Deane Prostate Health and Research Center at The Mount Sinai Medical Center,both in New York City.
Roger Sinclair Kirby FRCS(Urol),FEBU is a British retired prostate surgeon and professor of urology,researcher,writer on men's health and prostate disease,founding editor of the journal Prostate Cancer and Prostatic Diseases and Trends in Urology and Men's Health and a fundraiser for prostate disease charities,best known for his use of the da Vinci surgical robot for laparoscopic prostatectomy in the treatment of prostate cancer. He is a co-founder and president of the charity The Urology Foundation (TUF),vice-president of the charity Prostate Cancer UK,trustee of the King Edward VII's Hospital and as of 2020 is president of the Royal Society of Medicine (RSM),London.
Peter T. Scardino is an American cancer surgeon,researcher,and author expert in genitourinary and urological cancers particularly cancer of the prostate. He is chair of the Department of Surgery at Memorial Sloan Kettering Cancer Center.
Arie S. Belldegrun,FACS,is an Israeli-American urologic oncologist,billionaire businessman and investor.
Michael D. Stifelman Michael D. Stifelman,M.D.,is Chair of Urology at Hackensack University Medical Center,Director of Robotic Surgery at Hackensack Meridian Health,and Professor and Inaugural Chair of Urology at Hackensack Meridian School of Medicine.
Seviteronel is an experimental cancer medication which is under development by Viamet Pharmaceuticals and Innocrin Pharmaceuticals for the treatment of prostate cancer and breast cancer. It is a nonsteroidal CYP17A1 inhibitor and works by inhibiting the production of androgens and estrogens in the body. As of July 2017,seviteronel is in phase II clinical trials for both prostate cancer and breast cancer. In January 2016,it was designated fast-track status by the United States Food and Drug Administration for prostate cancer. In April 2017,seviteronel received fast-track designation for breast cancer as well.
Kevin M. Slawin is an American physician and the founder of Bellicum Pharmaceuticals and the Vanguard Urologic Institute at Memorial Hermann Medical Group. He was also the Director of Urology at Memorial Hermann Hospital. Slawin specializes in the diagnosis and treatment of urologic cancers and robotic surgery. He is also possesses patents related to the advancement of prostate cancer diagnosis,staging and treatment and to the cellular immunotherapy of cancer.
Vipul R. Patel,FACS is the founder and Medical Director of the Florida Hospital Global Robotics Institute,founder and Vice President of the Society of Robotic Surgery,and founder and Editor Emeritus of The Journal of Robotic Surgery. He is board certified by the American Urological Association and specializes in robotic surgery for prostate cancer. As of June,2023 he performed his 17,000th robotic-assisted prostatectomy. The large volume of prostatectomies he has performed has enabled him to amass a large amount of statistical evidence regarding the efficacy of robotic techniques which has been used in developing and refining techniques. Patel credits the use of robotic assisted surgery with helping surgeons achieve better surgical outcomes with the "trifecta" of cancer control,continence and sexual function. In the course of his career Patel has led and participated in studies that have resulted in developing improved outcomes for robotic surgery and urologic treatment.
Donald Straley Coffey was the Catherine Iola and J. Smith Michael distinguished professor of urology at Johns Hopkins University School of Medicine and subsequently professor emeritus. He had a primary appointment in urology and secondary appointments in oncology,pharmacology and pathology.
Kenneth J. Pienta is a medical doctor and the Donald S. Coffey professor of urology and professor of oncology and pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He also serves as the director of research at the Brady Urological Institute.
Oliver Sartor is an American oncologist and research scientist. He is currently the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research,Medicine and Urology Departments at the Tulane School of Medicine in New Orleans,Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. Sartor also serves as the editor-in-chief of the bimonthly journal Clinical Genitourinary Cancer that mainly focuses on research in genitourinary oncology.
Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
